S 1785 — Fair AMP Act
Last action — Read twice and referred to the Committee on Finance.
-
✓Introduced
-
2In Committee
-
3Passed Senate
-
4Passed House
-
5To Executive
-
6Enacted
This bill died with 116th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
This bill is no longer active — its legislative session has ended, so there are no live odds of enactment. It would have to be reintroduced in the current session to move again.
Summary
Fair and Accurate Medicaid Pricing Act of 2019 or the Fair AMP Act This bill alters certain requirements and definitions under the Medicaid Drug Rebate Program relating to rebate calculations. Specifically, the bill repeals the requirement that drug manufacturers include the prices of certain authorized generic drugs when determining the average manufacturer price (AMP) of brand-name drugs (also known as a "blended AMP"), and excludes manufacturers from the definition of "wholesalers" for purposes of rebate calculations.
Bill Text
- Introduced Introduced in Senate Current html June 11, 2019
Compared against current U.S. Code AI-generated reading aid — verify against the official bill.
The bill amends the Social Security Act to exclude authorized generic drugs from the calculation of average manufacturer price for Medicaid drug rebates.
-
42 U.S.C. 1396r-8(k)(1)
Inclusion→ ExclusionChanges the title from 'Inclusion' to 'Exclusion' to clarify the classification of authorized generic drugs.
-
42 U.S.C. 1396r-8(k)(1)
a new drug application→ the manufacturer's new drug applicationSpecifies that it refers to the manufacturer's application for clarity.
-
42 U.S.C. 1396r-8(k)(1)
inclusive→ exclusiveAlters the term from 'inclusive' to 'exclusive' to reflect the exclusion of authorized generic drugs.
-
42 U.S.C. 1396r-8(k)(11)
manufacturers,Excludes manufacturers from the definition of wholesaler.
-
42 U.S.C. 1396r-8(k)(11)
manufacturer's andFurther clarifies the definition by removing references to manufacturers.
Action History
-
Introduced in Senate
-
Read twice and referred to the Committee on Finance.
Sponsors
- Margaret Wood Hassan · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 546 not signed on
Sponsors (1)
- Hassan, Margaret Wood Democratic
Co-sponsors (0)
None.
Not signed on (546)
546 members have not signed on to this bill.
Show all 546 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- What does S 1785 do?
- Fair and Accurate Medicaid Pricing Act of 2019 or the Fair AMP Act This bill alters certain requirements and definitions under the Medicaid Drug Rebate Program relating to rebate calculations. Specifically, the bill repeals the requirement that drug manufacturers include the prices of certain authorized generic drugs when determining the average manufacturer price (AMP) of brand-name drugs (also known as a "blended AMP"), and excludes manufacturers from the definition of "wholesalers" for purposes of rebate calculations.
- Who sponsors S 1785?
- S 1785 is sponsored by Hassan, Margaret Wood (Democratic).
- What is the current status of S 1785?
- This bill died with 116th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
- Where can I track S 1785?
- Track S 1785 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on S 1785
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of S 1785
Last checked for changes 3 months ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →